Cardax Inc (CE) (CDXI) Quote

CDXI one for 200 reverse split. **PPS closed at .0475.

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

Two year low is 7 cents. Retest the low.

.0134 up selling slowed down

Nice bump today...!

Excellent! This is just the beginning. More international markets opening soon and the second generation product CDX-085 is a game changer.

https://www.otcmarkets.com/stock/CDXI/news/Cardax-Inks-Deal-to-Distribute-ZanthoSyn-in-China?id=183742

Yeah there was a lot of bogus press from competitors that have inferior product. It’s been refuted and the product and company are completely legitimate. This will climb.

Someone wanted out.

Get on board and hang on. We only have one direction. Mind you this is not a day trade. Get in stay in for 18 months. Upgrade your life.

Time to buy

I expect a pullback after this initial buy order from GNC which will be a good time to load more but this is a strategic keeper. Going to a few dollars in a couple years. Excellent product!!! Absolutely revolutionary anti-inflammatory! Try ZanthoSyn available at GNC and you will see why this stock is going up. Thanks for the tip on INMG.

Nice jump dude! I just happened to see this today, if I would of known I would of purchased. I like to diversify my investments but I have been heavily focused on, "INMG." Congratulations to your investment.

I told y'all to get on board!

Awesome! This ones going off. Just rolled out nationwide in GNC!

Interesting pop

Cardax! Get it now! We just went nationwide with GNC soon to be on EVERY shelf!

Buy and hold! Zanthosyn is going nationwide!

Is anybody else watching this company?

CDXI bullish 0.11

What I've able to research this company has potential to be a runner but pps stagnant and the board is dead. Anyone that can supply me the SS and float would be appreciated. TIA

Selling all Month.

Slow climber at .59

Amazing how pure unadulterated toxic sewage spews.

6 members...small, but growing

Once we see this above 10 or 20 followers this will light up. Only matter of time cause once people realize board members from Amgen, and Novartis are behind CDXI this will run.

Just got to spread the word...news would help as well

people behind deal are big

The people on their board are real deal biotech people. Even have guy who serves on CDXI board, and also serves on Amgen board currently as well. Thats major!

Astaxanthin sounds like an interesting product and with 2 big time partnerships in BASF and Capsugel I'm a bit surprised to see this tanking and currently trading at the 52 week low.

Cardax CEO David Watumall on Stock Radio a couple days ago.

http://thestockradio.com/cdxi-cardax-inc-ceo-david-watumall/

SeeThruEquity target price $1.00

http://www.kcentv.com/story/26713309/seethruequity-initiates-research-coverage-on-cardax-inc-with-a-target-price-of-100

Boom, hit .64...load up kiddies

major names behind this stock

CDXI has former CFO of Novartis, wow!!

$CDXI Offers Alternative to Tylenol, Secures Major Partnerships

(NEW YORK)--Cardax, Inc. (OTC:CDXI), a development stage, life sciences company focused on introducing nutraceutical and pharmaceutical products aimed at reducing inflammation and oxidative stress, closes major agreements to develop new anti-inflammatory products.

Alternative to Acetaminophen (Tylenol)

As many have become aware over the past few years, the use of popular over-the-counter pain relievers containing acetaminophen, such as with Tylenol and other name brand pain relievers, has shown to cause liver damage from overuse, especially people prone to liver issues.

An example, if you did not know, it is highly recommended you don't take acetaminophen products to treat a hangover as the effects of the acetaminophen, and the bodies processing of the alcohol, has shown to cause extreme stress on the liver, and under prolonged use can cause permanent damage.

In addition, there are also issues with people with standing liver disease (unrelated to alcohol) who also can not benefit from the effects of acetaminophen as an over-the-counter pain reliever. This sets up a multi-billion dollar market for alternatives to this popular over-the-counter medicine, and CDXI has that with astaxanthin.

Experienced Board of Directors

If you want to get a good idea on why CDXI stands out from most other penny stocks, then take a look at just a sample of who sits on their Board of Directors.

Mr. George Bickerstaff held various positions with Novartis International AG, a global pharmaceuticals and consumer health company, including Chief Financial Officer of Novartis Pharma AG from October 2000 to May 2005. Ms. Tamar Howson served as Senior Vice President, Corporate and Business Development at Bristol-Myers Squibb from 2001 to 2007.

Mr. Bickerstaff and Ms. Howson, are both currently members of the Board of Directors with CDXI.

Major Partnership Agreements

CDXI recently closed partnership deals with BASF and Capsugel to develop and bring new anti-inflammatory products to market, and commercialization under revenue sharing agreements.

BASF, the world's largest chemical company, has licensed exclusive rights from CDXI for the commercialization of nature-identical, synthetic astaxanthin, ASTX-1, as a nutraceutical. With lower regulatory restrictions on nutraceuticals, the product approval and introduction should move much faster than a pharmaceutical drug, allowing BASF and CDXI to have a product available for sale in 2015.

Add together CDXI experienced Board with years of history in major pharmaceutical companies, their partnership agreements with major drug developers, and a product that provides an alternative to popular over-the-counter drugs, such as Tylenol, and CDXI may be one of those few "real deal" companies not normally found on the OTC exchange.

ask .51

Also Bristol-Myers Squibb???

Tamar D. Howson , age 65, will serve as a director of the Company commencing June 16, 2014. She has served as an independent corporate business development and strategy consultant to life science companies since 2011. From 2009 to 2011, she provided business development support to life sciences companies as a member of the transaction team at JSB-Partners. From 2007 to 2008, Ms. Howson served as Executive Vice President, Corporate Business Development at Lexicon Pharmaceuticals. From 2001 to 2007, Ms. Howson served as Senior Vice President, Corporate and Business Development at Bristol-Myers Squibb.

former CFO of Novartis on CDXI board...wow!

George W. Bickerstaff, III , age 59, will serve as a director of the Company commencing June 16, 2014. Mr. Bickerstaff is currently a Managing Director of M.M. Dillon & Co., LLC, which he joined in 2005. Prior to joining M.M. Dillon & Co., LLC, Mr. Bickerstaff held various positions with Novartis International AG, a global pharmaceuticals and consumer health company, including Chief Financial Officer of Novartis Pharma AG from October 2000 to May 2005.

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10053109

That's major!

Real deal company

this thing is way under the radar, and looks like a real deal company. Wouldnt be shocked to see this as acquisition target when they get a few drugs in pipeline. Still doing research...anyone know the float?

Cardax doing big things!! Google their website and check out their investor presentation.. Also have two press releases in last 2-3 weeks

Koffee Corner Inc., KOFF changed to Cardax Inc., CDXI:

http://www.otcbb.com/asp/dailylist_detail.asp?d=02/20/2014&mkt_ctg=OTCBB

KOFF is looking great at this level

Starting to get some hits, should have grabbed $1.60 but I was too slow....sigh.

Cardax closes merger; stock set to trade on Monday

http://www.staradvertiser.com/s?action=login&f=y&id=244494821

Cardax Pharmaceuticals becomes Hawaii’s 16th publicly-traded company

http://www.bizjournals.com/pacific/news/2014/02/07/cardax-pharmaceuticals-becomes.html

Merger with Cardax Pharma, Inc is complete.

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9758981

This RM actually looks pretty decent for once, Cardax has had a partnership with BASF, the worlds largest chemical company for around 7 years now.

You don't see penny stocks with relationships like this every day.

http://www.bizjournals.com/pacific/stories/2006/12/04/daily6.html?page=all

Interesting looking RM coming with Cardax Pharmaceuticals

http://www.cardaxpharma.com/

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9638117

http://www.hispanicbusiness.com/2013/11/30/agreement_enables_isle-based_biotech_firm_cardax.htm

Yeah your probably right, just looks like a small coffee shop in downtown Houston that wants to raise the capital to open a couple new locations.

Wouldn't surprise me to see a stock promotion here someday.

http://www.koffeekornerinc.com/


Company Description

KOFFEE KORNER INC. (“Koffee Korner”, “we”, “us” or the “Company”) was initially
formed as a Texas Corporation in July 2003 and became a Delaware corporation in
February 2012.

Koffee Korner is a single location retailer of specialty coffee located on the
2 nd floor mezzanine level of a high rise

building in Houston, Texas. Koffee
Korner purchases its coffee, food, tea and restaurant supplies from its
principle supplier SYSCO and sells rich-brewed coffees, Italian-style espresso
beverages, cold blended beverages, and complementary food items which include
bakery items, sandwiches prepared by our staff, fruit and yogurt, a selection
of teas, and beverage-related accessories and equipment, prepared by our staff
and sold through our retail location. 85% of our sales are coffee sales (which
include brewed coffees, Italian-style espresso beverages and cold blended
beverages), 10% of our sales are food items (which include bakery items,
sandwiches prepared by our staff, fruit and yogurt), and 5% are teas and
beverage-related accessories and equipment. Occasionally, we run out of an item
and purchase small amounts of that item locally to tide us over until our next
delivery from SYSCO. The majority of our customers come from the tenants in our
building. We do get some foot traffic as we are in downtown Houston. We
estimate that 90% of our business is generated by the tenants of our building
and 10% of our business is generated by foot traffic. We estimate 85% of our
customers consume our products via takeaway and 15% of our customers consume
our products on our premises. We had revenues of $72,692 and a loss of
$(9,735) during our fiscal year ended March 31, 2012. We had revenues of
$16,917 and a loss of $(1,820) during the quarter ended June 30, 2012.

Given our recent rate of negative cash flow in our operations, which is
approximately $600 per month, as well as the likelihood that our cash burn rate
will increase once we become a reporting company due to increased accounting,
audit, attorney, and EDGAR professional fees of approximately $5,000 per
quarter, we believe that unless gross profits increase we do not have
sufficient capital to carry on operations past June of 2013, but we plan to
raise additional capital in a Regulation D Rule 505 exemption private placement
equity offering six months after the effective date of this prospectus, or if
current proposed regulations are adopted, three months from the date of this
prospectus, to secure the funds needed to finance our plan of operation for
fiscal year 2013 and overcome the uncertainty of our ability to continue as a
going concern. This $50,000 raise would allow us to continue for approximately
24 months past June 2013 at the current burn rate. However, this is a forward-
looking statement, and there may be changes that could consume available
resources before such time. Our contingency plan if the funds cannot be raised
is to; 1) have the company seek a bank credit line; 2) receive loans from our
officers; 3) private equity investments or debt financing from individuals or
entities. Our long term capital requirements and the adequacy of our available
funds will depend on many factors, including the eventual reporting company
costs and public relations fees, among others. If we are unable to raise
additional capital or generate sufficient revenue we will have to curtail or
cease our operations.

The Company’s objective is to obtain the resources to open an additional three
new locations in the Houston, Texas metropolitan area during the next two to
three years. However, there can be no assurance that we will ever open any
additional locations. Management estimates that the cost of establishing
additional retail locations will be approximately $250,000 per location.
Management hopes to be in a position to open additional locations in the next
24 to 36 months. In order to be able to obtain the resources to open additional
locations, management will need to raise money, find suitable locations and
suitable personnel to run the new locations. We have had early stage
discussions with investors about potential investment in our firm at a future
date. No assurance can be made that such financing would be available, and if
available it may take either the form of debt or equity. In either case, the
financing could have a negative impact on our financial condition and our
shareholders. We have no commitments for any financing and cannot assure you
that we will realize this goal.

-----

Koffee Korner Inc.

6560 Fannin St., Suite 245
Houston, TX 77030-2728
Telephone no : (713) 795-0011
Our website : www.KoffeeKornerInc.com.


Read more: www.nasdaq.com/markets/ipos/company/koffee-korner-inc-882850-70008#ixzz2cbmdccVJ

Hummmmm will have to keep an eye on this one. Probably tank to under .10 with no volume, sit dormant for a few months, then a few spikes in volume, consolidation, then a major pump......